Journal of clinical virology plus最新文献

Performance evaluation of the Qiagen BK virus ASR on the NeuMoDx system NeuMoDx系统上的Qiagen BK病毒ASR性能评估

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2024-11-14 DOI: 10.1016/j.jcvp.2024.100198

Amorce Lima, Luciano Soares, Caroline Simmons, Laura Rowe, Dominic Uy, Deanna Becker, Suzane Silbert

Background

BK virus (BKV) is the main cause of polyomavirus‐associated nephropathy in kidney transplant patients and hemorrhagic cystitis in bone marrow recipients. BKV quantitation by PCR is crucial in diagnostic and therapeutic management of transplant patients infected with BKV. We evaluated the performance of the Qiagen BKV ASR for the quantification of BKV on the NeuMoDx™ 96 System and compared the results to our standard of care (SOC) test, the Diasorin BKV ASR on the Liaison® MDX.

Methods

The analytical performance was assessed using commercially available BKV Panels that meet the 1^st WHO International Standards for BKV nucleic acid amplification techniques. The clinical performance was evaluated using 204 residual plasma and urine samples previously identified with the SOC assay.

Results

The assay exhibited a strong linear correlation (R² = 0.9985) with the reference panel and an excellent analytical accuracy (R² = 0.9976). The LoD was determined to be 50 IU/mL with remarkable precision within and between days (SDEV 0.00—0.57 and 0.05—0.31, respectively). Of the 204 samples, only 10 (4.9 %) were discordant (PPA = 92.37 %; NPA = 100 %). Although the Qiagen BKV ASR quantified BKV DNA at an average of 0.48 Log IU/mL lower than the SOC, it showed a strong concordance to the SOC results. Compared to the SOC, the Qiagen BKV ASR had a more automated workflow, with less hands-on time, leading to quicker turnaround time.

Conclusion

The Qiagen BKV ASR is specific, sensitive, and accurate in quantifying BKV in plasma and urine specimens on the fully automated NeuMoDx™ 96 System.

背景BK病毒（BKV）是肾移植患者多瘤病毒相关性肾病和骨髓受者出血性膀胱炎的主要病因。在对感染 BKV 的移植患者进行诊断和治疗管理时，通过 PCR 对 BKV 进行定量至关重要。我们评估了Qiagen BKV ASR在NeuMoDx™ 96系统上定量检测BKV的性能，并将结果与我们的标准检测（SOC）--Liaison® MDX上的Diasorin BKV ASR--进行了比较。结果该检测方法与参考试剂盒呈较强的线性相关（R² = 0.9985），分析准确度极高（R² = 0.9976）。LoD被确定为50 IU/mL，天内和天间的精确度非常高（SDEV分别为0.00-0.57和0.05-0.31）。在 204 份样本中，只有 10 份（4.9%）不一致（PPA = 92.37%；NPA = 100%）。虽然Qiagen BKV ASR对BKV DNA的定量平均比SOC低0.48 Log IU/mL，但它与SOC的结果显示出很强的一致性。结论在全自动NeuMoDx™ 96系统上，Qiagen BKV ASR能特异、灵敏、准确地定量血浆和尿液标本中的BKV。

{"title":"Performance evaluation of the Qiagen BK virus ASR on the NeuMoDx system","authors":"Amorce Lima, Luciano Soares, Caroline Simmons, Laura Rowe, Dominic Uy, Deanna Becker, Suzane Silbert","doi":"10.1016/j.jcvp.2024.100198","DOIUrl":"10.1016/j.jcvp.2024.100198","url":null,"abstract":"<div><h3>Background</h3><div>BK virus (BKV) is the main cause of polyomavirus‐associated nephropathy in kidney transplant patients and hemorrhagic cystitis in bone marrow recipients. BKV quantitation by PCR is crucial in diagnostic and therapeutic management of transplant patients infected with BKV. We evaluated the performance of the Qiagen BKV ASR for the quantification of BKV on the NeuMoDx™ 96 System and compared the results to our standard of care (SOC) test, the Diasorin BKV ASR on the Liaison® MDX.</div></div><div><h3>Methods</h3><div>The analytical performance was assessed using commercially available BKV Panels that meet the 1<sup>st</sup> WHO International Standards for BKV nucleic acid amplification techniques. The clinical performance was evaluated using 204 residual plasma and urine samples previously identified with the SOC assay.</div></div><div><h3>Results</h3><div>The assay exhibited a strong linear correlation (R² = 0.9985) with the reference panel and an excellent analytical accuracy (R² = 0.9976). The LoD was determined to be 50 IU/mL with remarkable precision within and between days (SDEV 0.00—0.57 and 0.05—0.31, respectively). Of the 204 samples, only 10 (4.9 %) were discordant (PPA = 92.37 %; NPA = 100 %). Although the Qiagen BKV ASR quantified BKV DNA at an average of 0.48 Log IU/mL lower than the SOC, it showed a strong concordance to the SOC results. Compared to the SOC, the Qiagen BKV ASR had a more automated workflow, with less hands-on time, leading to quicker turnaround time.</div></div><div><h3>Conclusion</h3><div>The Qiagen BKV ASR is specific, sensitive, and accurate in quantifying BKV in plasma and urine specimens on the fully automated NeuMoDx™ 96 System.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 1","pages":"Article 100198"},"PeriodicalIF":1.6,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142661754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correlation of cytokine storm with ocular fundus abnormalities in critically ill patients with severe viral pneumonia 重症病毒性肺炎重症患者细胞因子风暴与眼底异常的相关性

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2024-11-09 DOI: 10.1016/j.jcvp.2024.100196

Yun Yu , Yun-jiao Zhao , Qi-hang Zhou, Xiao-yin Zhou, Yu-qing Lan, Hai-jun Gong

Purpose

To investigate the relationship between ocular fundus abnormalities and cytokines in patients with severe viral pneumonia, aiming to provide targeted diagnostic recommendations.

Methods

We assessed critically ill patients with severe viral pneumonia and categorized them into the survivor (17 patients, 33 eyes) and deceased (30 patients, 58 eyes) groups. Spearman's correlation analysis was used to assess associations between cytokine levels and fundus abnormalities.

Results

In the deceased group, the vascular fractal dimension (FD) and vessel density (VD) were lower and negatively correlated with interleukin 2 (IL-2), IL-8, IL-10, interferon (IFN)-α, IFN-γ, IL-1β, IL-12, and IL-6 but positively correlated with IL-5. In the survivor group, arterial dilatation and reduced curvature were positively correlated with IL-6 and negatively correlated with IL-2 and IL-12; moreover, venous abnormalities were negatively correlated with IL-5, IL-10, and tumor necrosis factor (TNF)-α. In the deceased group, venous abnormalities were positively correlated with IL-10 and negatively correlated with IL-5, IL-1β, and TNF-α. The cup-to-disc ratio (CDR) was lower in the deceased group, with a significant reduction in rim width (RW), especially in the superior region. In the survivor group, the CDR was negatively correlated with IL-10, while in the deceased group, it was positively correlated with IL-6. RW was positively correlated with IL-1β, IL-5, and IL-10 in the survivor group and with IL-10, IL-12, and IL-17 in the deceased group.

Conclusion

Fundus vascular abnormalities and optic disc edema are associated with cytokine levels in patients with severe viral pneumonia, with significant differences between survivors and deceased patients.

目的研究重症病毒性肺炎患者眼底异常与细胞因子之间的关系，旨在提供有针对性的诊断建议。方法我们对重症病毒性肺炎重症患者进行了评估，并将其分为存活组（17 例患者，33 眼）和死亡组（30 例患者，58 眼）。结果在死亡组中，血管分形维度（FD）和血管密度（VD）较低，且与白细胞介素 2（IL-2）、IL-8、IL-10、干扰素（IFN）-α、IFN-γ、IL-1β、IL-12 和 IL-6 呈负相关，但与 IL-5 呈正相关。在幸存者组中，动脉扩张和弯曲度降低与IL-6呈正相关，与IL-2和IL-12呈负相关；此外，静脉异常与IL-5、IL-10和肿瘤坏死因子（TNF）-α呈负相关。在死亡组中，静脉异常与 IL-10 呈正相关，与 IL-5、IL-1β 和 TNF-α 呈负相关。死亡组的杯盘比（CDR）较低，边缘宽度（RW）显著减少，尤其是在上部区域。在存活组中，CDR与IL-10呈负相关，而在死亡组中，CDR与IL-6呈正相关。结论重症病毒性肺炎患者的眼底血管异常和视盘水肿与细胞因子水平有关，幸存者和死亡患者之间存在显著差异。

{"title":"Correlation of cytokine storm with ocular fundus abnormalities in critically ill patients with severe viral pneumonia","authors":"Yun Yu , Yun-jiao Zhao , Qi-hang Zhou, Xiao-yin Zhou, Yu-qing Lan, Hai-jun Gong","doi":"10.1016/j.jcvp.2024.100196","DOIUrl":"10.1016/j.jcvp.2024.100196","url":null,"abstract":"<div><h3>Purpose</h3><div>To investigate the relationship between ocular fundus abnormalities and cytokines in patients with severe viral pneumonia, aiming to provide targeted diagnostic recommendations.</div></div><div><h3>Methods</h3><div>We assessed critically ill patients with severe viral pneumonia and categorized them into the survivor (17 patients, 33 eyes) and deceased (30 patients, 58 eyes) groups. Spearman's correlation analysis was used to assess associations between cytokine levels and fundus abnormalities.</div></div><div><h3>Results</h3><div>In the deceased group, the vascular fractal dimension (FD) and vessel density (VD) were lower and negatively correlated with interleukin 2 (IL-2), IL-8, IL-10, interferon (IFN)-α, IFN-γ, IL-1β, IL-12, and IL-6 but positively correlated with IL-5. In the survivor group, arterial dilatation and reduced curvature were positively correlated with IL-6 and negatively correlated with IL-2 and IL-12; moreover, venous abnormalities were negatively correlated with IL-5, IL-10, and tumor necrosis factor (TNF)-α. In the deceased group, venous abnormalities were positively correlated with IL-10 and negatively correlated with IL-5, IL-1β, and TNF-α. The cup-to-disc ratio (CDR) was lower in the deceased group, with a significant reduction in rim width (RW), especially in the superior region. In the survivor group, the CDR was negatively correlated with IL-10, while in the deceased group, it was positively correlated with IL-6. RW was positively correlated with IL-1β, IL-5, and IL-10 in the survivor group and with IL-10, IL-12, and IL-17 in the deceased group.</div></div><div><h3>Conclusion</h3><div>Fundus vascular abnormalities and optic disc edema are associated with cytokine levels in patients with severe viral pneumonia, with significant differences between survivors and deceased patients.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 1","pages":"Article 100196"},"PeriodicalIF":1.6,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142661356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A prospective study to evaluate the clinical specificity of the cobas® MPX test kit for screening for HIV RNA, HCV RNA, and HBV DNA in blood donation samples using the cobas® 6800 system in HBV endemic areas 一项前瞻性研究，评估在 HBV 流行地区使用 cobas® 6800 系统筛查献血样本中 HIV RNA、HCV RNA 和 HBV DNA 的 cobas® MPX 检测试剂盒的临床特异性

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2024-11-07 DOI: 10.1016/j.jcvp.2024.100197

Lei Zhou , Lin Wang , Xiaofang Gong , Xiaochun Liu , Yaxuan Zou , Yingying Wang , Jinfeng Zeng , Liang Zang

Background

Nucleic acid testing (NAT) is widely used for screening blood donors for infectious diseases to enhance transfusion safety. Roche's advanced cobas® MPX assay detects human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) using the cobas® 6800/5800 Systems, based on real-time PCR technology, providing improved sensitivity. This study aims to evaluate the clinical sensitivity and specificity of the cobas® MPX assay and its effectiveness in identifying infected donors in HBV endemic areas, particularly those with occult HBV infection (OBI).

Materials and methods

A total of 12,067 donor samples from the Dalian Blood Center (DLBC, northern China) were tested for HIV, HCV, and HBV using both the cobas® MPX assay on the cobas® 6800 system and the previous generation cobas® TaqScreen MPX test v2.0 on the cobas s 201 system as the reference method. Testing was conducted using individual-donation testing (IDT) and primary pool of six donations (PP6), following the manufacturer's instructions and the operational procedures of the instruments. Samples with inconsistent results underwent repeated confirmation tests.

Results

Cobas® MPX demonstrated 100.00 % overall percent agreement (95 % CI, 99.22 %-100.00 %) for IDT and 99.89 % (95 % CI, 99.82 %-99.95 %) for PP6. Kappa coefficients were 1.0 for IDT and 0.76 for PP6. Cobas® MPX specificity was 100.00 % (95 % CI, 99.22 %-100.00 %) for IDT and 99.99 % (95 % CI, 99.94 %-100.00 %) for PP6. Sensitivity was 100.00 % (95 % CI, 2.50 %-100.00 %) for IDT and 86.67 % (95 % CI, 68.36 %-95.64 %) for PP6. A total of 12 HBV NAT-yield cases were detected by cobas® MPX.

Conclusion

Cobas® MPX demonstrated outstanding sensitivity and specificity in screening HIV, HCV, and HBV in routine blood donations, particularly enhancing occult HBV detection in endemic regions.

背景核酸检测（NAT）被广泛用于对献血者进行传染病筛查，以提高输血安全性。罗氏公司先进的cobas® MPX检测法基于实时PCR技术，使用cobas® 6800/5800系统检测人类免疫缺陷病毒（HIV）、丙型肝炎病毒（HCV）和乙型肝炎病毒（HBV），提高了灵敏度。本研究旨在评估 cobas® MPX 检测法的临床灵敏度和特异性，以及它在识别 HBV 流行地区受感染供体（尤其是隐性 HBV 感染（OBI）供体）方面的有效性。材料与方法采用cobas® 6800系统上的cobas® MPX检测法和cobas s 201系统上的上一代cobas® TaqScreen MPX检测法v2.0作为参考方法，对大连血液中心（DLBC，中国北方）的12,067份献血者样本进行了HIV、HCV和HBV检测。检测采用个体捐献检测（IDT）和六次捐献初选库（PP6），按照生产商的说明和仪器的操作程序进行。结果Cobas® MPX在IDT和PP6中的总体一致性分别为100.00%（95% CI，99.22%-100.00%）和99.89%（95% CI，99.82%-99.95%）。IDT 的卡帕系数为 1.0，PP6 为 0.76。IDT 和 PP6 的 Cobas® MPX 特异性分别为 100.00 %（95 % CI，99.22 %-100.00 %）和 99.99 %（95 % CI，99.94 %-100.00 %）。IDT 的灵敏度为 100.00 %（95 % CI，2.50 %-100.00 %），PP6 的灵敏度为 86.67 %（95 % CI，68.36 %-95.64 %）。结论cobas® MPX在常规献血中筛查HIV、HCV和HBV方面表现出了出色的灵敏度和特异性，尤其是在流行地区提高了隐性HBV的检测能力。

{"title":"A prospective study to evaluate the clinical specificity of the cobas® MPX test kit for screening for HIV RNA, HCV RNA, and HBV DNA in blood donation samples using the cobas® 6800 system in HBV endemic areas","authors":"Lei Zhou , Lin Wang , Xiaofang Gong , Xiaochun Liu , Yaxuan Zou , Yingying Wang , Jinfeng Zeng , Liang Zang","doi":"10.1016/j.jcvp.2024.100197","DOIUrl":"10.1016/j.jcvp.2024.100197","url":null,"abstract":"<div><h3>Background</h3><div>Nucleic acid testing (NAT) is widely used for screening blood donors for infectious diseases to enhance transfusion safety. Roche's advanced cobas® MPX assay detects human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) using the cobas® 6800/5800 Systems, based on real-time PCR technology, providing improved sensitivity. This study aims to evaluate the clinical sensitivity and specificity of the cobas® MPX assay and its effectiveness in identifying infected donors in HBV endemic areas, particularly those with occult HBV infection (OBI).</div></div><div><h3>Materials and methods</h3><div>A total of 12,067 donor samples from the Dalian Blood Center (DLBC, northern China) were tested for HIV, HCV, and HBV using both the cobas® MPX assay on the cobas® 6800 system and the previous generation cobas® TaqScreen MPX test v2.0 on the cobas s 201 system as the reference method. Testing was conducted using individual-donation testing (IDT) and primary pool of six donations (PP6), following the manufacturer's instructions and the operational procedures of the instruments. Samples with inconsistent results underwent repeated confirmation tests.</div></div><div><h3>Results</h3><div>Cobas® MPX demonstrated 100.00 % overall percent agreement (95 % CI, 99.22 %-100.00 %) for IDT and 99.89 % (95 % CI, 99.82 %-99.95 %) for PP6. Kappa coefficients were 1.0 for IDT and 0.76 for PP6. Cobas® MPX specificity was 100.00 % (95 % CI, 99.22 %-100.00 %) for IDT and 99.99 % (95 % CI, 99.94 %-100.00 %) for PP6. Sensitivity was 100.00 % (95 % CI, 2.50 %-100.00 %) for IDT and 86.67 % (95 % CI, 68.36 %-95.64 %) for PP6. A total of 12 HBV NAT-yield cases were detected by cobas® MPX.</div></div><div><h3>Conclusion</h3><div>Cobas® MPX demonstrated outstanding sensitivity and specificity in screening HIV, HCV, and HBV in routine blood donations, particularly enhancing occult HBV detection in endemic regions.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 1","pages":"Article 100197"},"PeriodicalIF":1.6,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142661355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A rapid review of the epidemiology and combating strategies of hepatitis C virus infection in Ghana 加纳丙型肝炎病毒感染流行病学和防治策略快速审查

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2024-10-09 DOI: 10.1016/j.jcvp.2024.100195

Marcarious M. Tantuoyir , Muhammed Camara , Marjan Sohrabi , SeyedAhmad SeyedAlinaghi , Zahra Ahmadinejad

The contribution of viral hepatitis including hepatitis C virus (HCV) to morbidity and death is thought to be substantial in Ghana and should be accorded greater attention. Scopus, PubMed, and Web of Science databases were searched, as well as the Google Scholar search engine, for primary studies published from 1995–2023 inclusive. We specifically searched for primary studies as well as studies using both quantitative and qualitative methodologies. The country lacks population-based studies and comprehensive national HCV surveillance systems, making it difficult to estimate the true burden of HCV accurately. The prevalence of HCV infection is estimated to be between 1.75 and 3.4 % in Ghana. The predominant HCV genotype in the country is genotype 2, followed by genotype 1. The prevalence of genotypes 4, 5, and 6 is very low or nonexistent in Ghana. Older age (>50 years), male gender, and HCV genotype 1b are significantly associated with liver fibrosis and cirrhosis leading to hepatocellular carcinoma. Ghana is among the high-prevalence HCV infection countries. There is a high prevalence of cirrhosis among HCV-infected individuals, with older age and genotype 1b associated with an increased risk. Consequently, more efforts are needed to increase awareness and implementation of national guidelines.

在加纳，包括丙型肝炎病毒（HCV）在内的病毒性肝炎对发病和死亡的影响被认为是巨大的，应给予更多关注。我们在 Scopus、PubMed 和 Web of Science 数据库以及 Google Scholar 搜索引擎中搜索了 1995-2023 年间发表的主要研究。我们特别搜索了初级研究以及采用定量和定性方法的研究。该国缺乏基于人群的研究和全面的国家 HCV 监测系统，因此很难准确估计 HCV 的真实负担。据估计，加纳的 HCV 感染率在 1.75% 到 3.4% 之间。加纳的主要 HCV 基因型是基因 2 型，其次是基因 1 型。基因型 4、5 和 6 在加纳的发病率很低或根本不存在。高龄（50 岁）、男性和 HCV 基因型 1b 与肝纤维化和导致肝细胞癌的肝硬化密切相关。加纳是丙型肝炎病毒感染高发国家之一。在感染 HCV 的人群中，肝硬化的发病率很高，年龄越大、基因型 1b 的风险越高。因此，需要做出更多努力，提高对国家指导方针的认识和执行力度。

{"title":"A rapid review of the epidemiology and combating strategies of hepatitis C virus infection in Ghana","authors":"Marcarious M. Tantuoyir , Muhammed Camara , Marjan Sohrabi , SeyedAhmad SeyedAlinaghi , Zahra Ahmadinejad","doi":"10.1016/j.jcvp.2024.100195","DOIUrl":"10.1016/j.jcvp.2024.100195","url":null,"abstract":"<div><div>The contribution of viral hepatitis including hepatitis C virus (HCV) to morbidity and death is thought to be substantial in Ghana and should be accorded greater attention. Scopus, PubMed, and Web of Science databases were searched, as well as the Google Scholar search engine, for primary studies published from 1995–2023 inclusive. We specifically searched for primary studies as well as studies using both quantitative and qualitative methodologies. The country lacks population-based studies and comprehensive national HCV surveillance systems, making it difficult to estimate the true burden of HCV accurately. The prevalence of HCV infection is estimated to be between 1.75 and 3.4 % in Ghana. The predominant HCV genotype in the country is genotype 2, followed by genotype 1. The prevalence of genotypes 4, 5, and 6 is very low or nonexistent in Ghana. Older age (>50 years), male gender, and HCV genotype 1b are significantly associated with liver fibrosis and cirrhosis leading to hepatocellular carcinoma. Ghana is among the high-prevalence HCV infection countries. There is a high prevalence of cirrhosis among HCV-infected individuals, with older age and genotype 1b associated with an increased risk. Consequently, more efforts are needed to increase awareness and implementation of national guidelines.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 4","pages":"Article 100195"},"PeriodicalIF":1.6,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142529509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Serologic evidence of dengue and chikungunya among patients with acute febrile illness in Ghana, 2016 – 2018 2016-2018年加纳急性发热性疾病患者中登革热和基孔肯雅热的血清学证据

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2024-09-29 DOI: 10.1016/j.jcvp.2024.100193

Deborah Pratt , Hayashi Takaya , Abigail Akua Abankwa , Yaw Awuku-Larbi , Stephen Nyarko , Esinam E Agbosu , Magdalene Ofori , Stella Bour , Dennis Laryea , Franklin Asiedu-Bekoe , Toshihiko Suzuki , Shoji Yamaoka , Joseph Humphrey Kofi Bonney

Objective

This study aimed to describe the exposure levels to Dengue and Chikungunya viruses among individuals presenting with febrile illnesses in Ghana between January 2016 to June 2018.

Methods

The study was conducted in health facilities in seven selected regions in Ghana; namely, Ashanti, Greater Accra, Northern, Upper West, Volta, and Western regions. Patients who met the case definition were enrolled in the study. A total of 1105 blood samples were collected from patients from 2016 to 2018 and serological analysis of Dengue and Chikungunya viruses were performed with ELISA IgM and IgG commercial kits (Abcam, Cambridge, UK).

Results

Analysed results indicated that Dengue and Chikungunya viruses showed seropositivity of 62.0 % and 40.0 % respectively. All processed samples tested negative for Dengue and Chikungunya using the Polymerase Chain Reaction (PCR) assay. Greater Accra and Ashanti regions recorded the highest positivity for Chikungunya and Dengue fever viruses respectively.

Conclusion

Though no detection of Dengue and Chikungunya using molecular tools, the seropositivity suggests the need for an established surveillance for arboviruses to monitor transmission of these pathogens for epidemic preparedness and response.

目标本研究旨在描述2016年1月至2018年6月期间加纳发热疾病患者的登革热和基孔肯雅病毒暴露水平。方法本研究在加纳七个选定地区的医疗机构进行，即阿散蒂、大阿克拉、北部、上西部、沃尔特和西部地区。符合病例定义的患者被纳入研究。从 2016 年到 2018 年，共采集了 1105 份患者血样，并使用 ELISA IgM 和 IgG 商用试剂盒（Abcam，英国剑桥）对登革热和基孔肯雅病毒进行了血清学分析。结果分析结果显示，登革热和基孔肯雅病毒的血清阳性率分别为 62.0% 和 40.0%。使用聚合酶链式反应（PCR）检测法对所有处理过的样本进行了登革热和基孔肯雅病毒阴性检测。大阿克拉地区和阿散蒂地区的基孔肯雅热和登革热病毒阳性率分别最高。结论虽然没有使用分子工具检测出登革热和基孔肯雅热，但血清阳性反应表明有必要建立虫媒病毒监测机制，以监测这些病原体的传播情况，从而为流行病的防备和应对做好准备。

{"title":"Serologic evidence of dengue and chikungunya among patients with acute febrile illness in Ghana, 2016 – 2018","authors":"Deborah Pratt , Hayashi Takaya , Abigail Akua Abankwa , Yaw Awuku-Larbi , Stephen Nyarko , Esinam E Agbosu , Magdalene Ofori , Stella Bour , Dennis Laryea , Franklin Asiedu-Bekoe , Toshihiko Suzuki , Shoji Yamaoka , Joseph Humphrey Kofi Bonney","doi":"10.1016/j.jcvp.2024.100193","DOIUrl":"10.1016/j.jcvp.2024.100193","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to describe the exposure levels to Dengue and Chikungunya viruses among individuals presenting with febrile illnesses in Ghana between January 2016 to June 2018.</div></div><div><h3>Methods</h3><div>The study was conducted in health facilities in seven selected regions in Ghana; namely, Ashanti, Greater Accra, Northern, Upper West, Volta, and Western regions. Patients who met the case definition were enrolled in the study. A total of 1105 blood samples were collected from patients from 2016 to 2018 and serological analysis of Dengue and Chikungunya viruses were performed with ELISA IgM and IgG commercial kits (Abcam, Cambridge, UK).</div></div><div><h3>Results</h3><div>Analysed results indicated that Dengue and Chikungunya viruses showed seropositivity of 62.0 % and 40.0 % respectively. All processed samples tested negative for Dengue and Chikungunya using the Polymerase Chain Reaction (PCR) assay. Greater Accra and Ashanti regions recorded the highest positivity for Chikungunya and Dengue fever viruses respectively.</div></div><div><h3>Conclusion</h3><div>Though no detection of Dengue and Chikungunya using molecular tools, the seropositivity suggests the need for an established surveillance for arboviruses to monitor transmission of these pathogens for epidemic preparedness and response.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 4","pages":"Article 100193"},"PeriodicalIF":1.6,"publicationDate":"2024-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142529510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HAART treatment with free provided medications for people living with HIV in Huzhou, China 中国湖州艾滋病病毒感染者免费接受 HAART 治疗

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2024-09-20 DOI: 10.1016/j.jcvp.2024.100191

Xiaofeng Li , Zhaowei Tong , Qingqiu Zeng , Meiling Xu , Bin Shen , Wei Zhang , Yan Zhang , Weihong Wang , Kefeng Qin

Background

For antiretroviral therapy (ART), drug combinations have been freely provided to people living with human immunodeficiency virus (PLWH) for treatment of acquired immunodeficiency syndrome (AIDS)in China. We have systematically analyzed the treatment results in Huzhou, Zhejiang Province.

Methods

Total 724 patients with HIV antibody positive from May 2005 to March 2023 at the age of 40.4±15.4 (15-82) years were treated with free provided drug combinations, including lamivudine (3TC), efavirenz (EFV) and tenofovir (TDF), or drugs at patient's own expense, includingbictegravir (BIC), emtricitabine (FTC) and tenofovir alafenamide (TAF). CD4+ T-cell count and viral load (VL) were detected before and after HAART treatment.

Results

Before and after HAART treatment, CD4+ T-cell count and viral load (VL) were measured. CD4+ T-cell count in 724 PLWH was from 269.2±178.9 to 453.8±243.3 cells/µl (p=0.0001), with 627(86.60%) cases increasing (221.0±204.6 cells/µl), 63(8.70%) decreasing (-96.0±84.1 cells/µl), 54(7.46%) cases no change. At the end of the treatment, 251(34.67%) cases were with CD4+ T-cell count>500.Viral load (VL)in 243 PLWHwas 14,474.4±62769.4 vs. 1,100.3±8513.1 copies/ml (p=0.0011), and with 181(74.49%) cases decreasing (-18,365.3±71,761.1 copies/ml), 14(5.76%) increasing (5,302.3±11,766.8 copies/ml), and 48 (19.75%) no change. Twenty-six patients died during the treatment period. There were no significant differences between results using free provided and paid drug combinations.

Conclusion

The free provided drug combinations increase CD4+ T-cell count and decrease viral load in PLWH, but about one-fourth of patients are considered as treatment failure. The improvement is needed for the HAART treatment.

背景在中国，人类免疫缺陷病毒感染者（PLWH）可免费接受抗逆转录病毒治疗（ART），以治疗获得性免疫缺陷综合征（AIDS）。我们对浙江省湖州市的治疗效果进行了系统分析。方法2005年5月至2023年3月，共收治724例HIV抗体阳性患者，年龄（40.4±15.4（15-82）岁，接受了免费提供的药物组合治疗，包括拉米夫定（3TC）、依非韦伦（EFV）和替诺福韦（TDF），或患者自费药物，包括比特拉韦（BIC）、恩曲他滨（FTC）和替诺福韦阿酚酰胺（TAF）。在 HAART 治疗前后，检测了 CD4+ T 细胞计数和病毒载量（VL）。结果在 HAART 治疗前后，检测了 CD4+ T 细胞计数和病毒载量（VL）。724 名 PLWH 的 CD4+ T 细胞计数从 269.2±178.9 cells/µl 升至 453.8±243.3 cells/µl（P=0.0001），其中 627 例（86.60%）增加（221.0±204.6 cells/µl），63 例（8.70%）减少（-96.0±84.1 cells/µl），54 例（7.46%）无变化。治疗结束时，251 例（34.67%）CD4+ T 细胞计数为 500。243 例 PLWH 的病毒载量（VL）为（14474.4±62769.4）拷贝数/毫升与（1100.3±8513.1）拷贝数/毫升（P=0.其中 181 例（74.49%）降低（-18,365.3±71,761.1 拷贝/毫升），14 例（5.76%）升高（5,302.3±11,766.8 拷贝/毫升），48 例（19.75%）无变化。26 名患者在治疗期间死亡。结论免费提供的药物组合可提高 PLWH 的 CD4+ T 细胞计数并降低病毒载量，但约四分之一的患者被视为治疗失败。HAART 治疗需要改进。

{"title":"HAART treatment with free provided medications for people living with HIV in Huzhou, China","authors":"Xiaofeng Li , Zhaowei Tong , Qingqiu Zeng , Meiling Xu , Bin Shen , Wei Zhang , Yan Zhang , Weihong Wang , Kefeng Qin","doi":"10.1016/j.jcvp.2024.100191","DOIUrl":"10.1016/j.jcvp.2024.100191","url":null,"abstract":"<div><h3>Background</h3><div>For antiretroviral therapy (ART), drug combinations have been freely provided to people living with human immunodeficiency virus (PLWH) for treatment of acquired immunodeficiency syndrome (AIDS)in China. We have systematically analyzed the treatment results in Huzhou, Zhejiang Province.</div></div><div><h3>Methods</h3><div>Total 724 patients with HIV antibody positive from May 2005 to March 2023 at the age of 40.4±15.4 (15-82) years were treated with free provided drug combinations, including lamivudine (3TC), efavirenz (EFV) and tenofovir (TDF), or drugs at patient's own expense, includingbictegravir (BIC), emtricitabine (FTC) and tenofovir alafenamide (TAF). CD4+ T-cell count and viral load (VL) were detected before and after HAART treatment.</div></div><div><h3>Results</h3><div>Before and after HAART treatment, CD4+ T-cell count and viral load (VL) were measured. CD4+ T-cell count in 724 PLWH was from 269.2±178.9 to 453.8±243.3 cells/µl (<em>p</em>=0.0001), with 627(86.60%) cases increasing (221.0±204.6 cells/µl), 63(8.70%) decreasing (-96.0±84.1 cells/µl), 54(7.46%) cases no change. At the end of the treatment, 251(34.67%) cases were with CD4+ T-cell count>500.Viral load (VL)in 243 PLWHwas 14,474.4±62769.4 vs. 1,100.3±8513.1 copies/ml (<em>p</em>=0.0011), and with 181(74.49%) cases decreasing (-18,365.3±71,761.1 copies/ml), 14(5.76%) increasing (5,302.3±11,766.8 copies/ml), and 48 (19.75%) no change. Twenty-six patients died during the treatment period. There were no significant differences between results using free provided and paid drug combinations.</div></div><div><h3>Conclusion</h3><div>The free provided drug combinations increase CD4+ T-cell count and decrease viral load in PLWH, but about one-fourth of patients are considered as treatment failure. The improvement is needed for the HAART treatment.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 4","pages":"Article 100191"},"PeriodicalIF":1.6,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142322935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Next generation sequencing-based transcriptome data mining for virus identification and characterization: Review on recent progress and prospects 基于下一代测序的转录组数据挖掘用于病毒鉴定和特征描述：最新进展和前景综述

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2024-09-18 DOI: 10.1016/j.jcvp.2024.100194

Mohammadreza Rahimian , Bahman Panahi

Advancements in next-generation sequencing (NGS) technologies and innovative bioinformatics tools have significantly accelerated virus discovery by analyzing of NGS data. This approach provides a cost-effective and efficient method for processing large datasets, allowing for rapid virus detection and identification. Researchers can comprehensively understand virus-host interactions by integrating data mining with other omics data, such as proteomics (the study of proteins) and metabolomics (the study of metabolic processes). Recent progress has significantly enhanced the efficiency and accuracy of virus identification by using a sophisticated NGS data mining approach. This study provides an in-depth discussion of these techniques, offering a detailed overview of workflows and applicable computational methods. Despite these advantages, the virus discovery process through data mining encounters obstacles such as ethical issues, the absence of standardized protocols for virus discovery procedures, and challenges in validation and interpretation. Addressing these obstacles is crucial for fully realizing the potential of NGS data mining in virus research. This review discusses current methodologies, recent advancements, and future directions to overcome these challenges, ultimately contributing to our understanding of viral diversity and virus-host dynamics.

下一代测序（NGS）技术和创新生物信息学工具的进步，大大加快了通过分析 NGS 数据发现病毒的速度。这种方法为处理大型数据集提供了一种经济高效的方法，可快速检测和识别病毒。研究人员可以通过将数据挖掘与蛋白质组学（蛋白质研究）和代谢组学（代谢过程研究）等其他全息数据相结合，全面了解病毒与宿主之间的相互作用。最近的进展是，通过使用复杂的 NGS 数据挖掘方法，大大提高了病毒鉴定的效率和准确性。本研究深入探讨了这些技术，详细介绍了工作流程和适用的计算方法。尽管有这些优势，但通过数据挖掘发现病毒的过程仍会遇到一些障碍，如伦理问题、缺乏病毒发现程序的标准化协议，以及验证和解释方面的挑战。要充分发挥 NGS 数据挖掘在病毒研究中的潜力，解决这些障碍至关重要。本综述讨论了克服这些挑战的现有方法、最新进展和未来方向，最终有助于我们了解病毒多样性和病毒-宿主动态。

{"title":"Next generation sequencing-based transcriptome data mining for virus identification and characterization: Review on recent progress and prospects","authors":"Mohammadreza Rahimian , Bahman Panahi","doi":"10.1016/j.jcvp.2024.100194","DOIUrl":"10.1016/j.jcvp.2024.100194","url":null,"abstract":"<div><p>Advancements in next-generation sequencing (NGS) technologies and innovative bioinformatics tools have significantly accelerated virus discovery by analyzing of NGS data. This approach provides a cost-effective and efficient method for processing large datasets, allowing for rapid virus detection and identification. Researchers can comprehensively understand virus-host interactions by integrating data mining with other omics data, such as proteomics (the study of proteins) and metabolomics (the study of metabolic processes). Recent progress has significantly enhanced the efficiency and accuracy of virus identification by using a sophisticated NGS data mining approach. This study provides an in-depth discussion of these techniques, offering a detailed overview of workflows and applicable computational methods. Despite these advantages, the virus discovery process through data mining encounters obstacles such as ethical issues, the absence of standardized protocols for virus discovery procedures, and challenges in validation and interpretation. Addressing these obstacles is crucial for fully realizing the potential of NGS data mining in virus research. This review discusses current methodologies, recent advancements, and future directions to overcome these challenges, ultimately contributing to our understanding of viral diversity and virus-host dynamics.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 4","pages":"Article 100194"},"PeriodicalIF":1.6,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266703802400019X/pdfft?md5=8839daa94af23784c8bcda03aa8fc6a2&pid=1-s2.0-S266703802400019X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142270705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiology of respiratory viruses before and during the COVID-19 pandemic in a tertiary care hospital in Southern Brazil 巴西南部一家三级医院在 COVID-19 大流行之前和期间的呼吸道病毒流行情况

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2024-09-13 DOI: 10.1016/j.jcvp.2024.100190

Veridiana Piva Richter , Fernanda de-Paris , Márcia Rosane Pires , Hugo Bock

Background

Respiratory viral infections affect millions of people worldwide and are life threatening for many of them. The viral seasonality leads to changes in the dynamics of respiratory infections and the importance of monitoring and surveillance of respiratory viruses becomes clearer.

Objectives

This study aims to analyze data from respiratory virus testing at the Hospital de Clínicas de Porto Alegre (HCPA) to evaluate their epidemiology from 2018 to 2021, observing their occurrence and seasonality before and after the onset of the SARS-CoV-2 pandemic.

Study design

In this study, data analysis was divided into four time periods, corresponding to 2018 to 2021. Anonymized patients diagnosed with influenza virus (FLU), human parainfluenza virus (HPIV), human respiratory syncytial virus (HRSV), SARS-CoV-2 virus, or human adenovirus (HAdV) were included. We conducted chi-square goodness-of-fit tests for each virus by year, and a p-value of <0.05 was considered statistically significant.

Results

All analyzed respiratory viruses presented reduced case numbers during the COVID-19 pandemic, except FLU, which showed an increase of four cases in 2021 compared to 2019. For most viruses, the lowest incidence of confirmed cases was found in 2020. Furthermore, when excluding SARS-CoV-2, HRSV presented the most positive cases during the studied period, except in 2020. Besides SARS-CoV-2, the FLU was the only other respiratory virus that recorded deaths. It was also possible to observe that the number of SARS-CoV-2 cases reduced from April 2021.

Conclusions

We observed that most respiratory tract viral infections decreased during the COVID-19 pandemic, and this result may be associated with the public interventions for containing the COVID-19 pandemic. Moreover, the reduction of these other viruses may have resulted from the measures for prevention conducted by HCPA.

背景全世界有数百万人受到呼吸道病毒感染的影响，其中许多人的生命受到威胁。本研究旨在分析阿雷格里港临床医院（HCPA）的呼吸道病毒检测数据，评估 2018 年至 2021 年的流行病学，观察 SARS-CoV-2 大流行前后的发生率和季节性。研究设计在本研究中，数据分析分为四个时间段，分别对应 2018 年至 2021 年。研究纳入了被诊断为流感病毒（FLU）、人类副流感病毒（HPIV）、人类呼吸道合胞病毒（HRSV）、SARS-CoV-2 病毒或人类腺病毒（HAdV）的匿名患者。我们按年份对每种病毒进行了齐次方拟合优度检验，P 值为 <0.05，则认为具有统计学意义。结果所有分析的呼吸道病毒在 COVID-19 大流行期间的病例数都有所减少，只有 FLU 除外，与 2019 年相比，2021 年的病例数增加了 4 例。就大多数病毒而言，2020 年的确诊病例数最低。此外，除 SARS-CoV-2 外，HRSV 是研究期间阳性病例最多的病毒，2020 年除外。除 SARS-CoV-2 外，卡介苗是唯一出现死亡病例的呼吸道病毒。结论我们发现，在 COVID-19 大流行期间，大多数呼吸道病毒感染有所减少，这可能与为遏制 COVID-19 大流行而采取的公共干预措施有关。此外，这些其他病毒的减少可能是由于 HCPA 采取了预防措施。

{"title":"Epidemiology of respiratory viruses before and during the COVID-19 pandemic in a tertiary care hospital in Southern Brazil","authors":"Veridiana Piva Richter , Fernanda de-Paris , Márcia Rosane Pires , Hugo Bock","doi":"10.1016/j.jcvp.2024.100190","DOIUrl":"10.1016/j.jcvp.2024.100190","url":null,"abstract":"<div><h3>Background</h3><div>Respiratory viral infections affect millions of people worldwide and are life threatening for many of them. The viral seasonality leads to changes in the dynamics of respiratory infections and the importance of monitoring and surveillance of respiratory viruses becomes clearer.</div></div><div><h3>Objectives</h3><div>This study aims to analyze data from respiratory virus testing at the Hospital de Clínicas de Porto Alegre (HCPA) to evaluate their epidemiology from 2018 to 2021, observing their occurrence and seasonality before and after the onset of the SARS-CoV-2 pandemic.</div></div><div><h3>Study design</h3><div>In this study, data analysis was divided into four time periods, corresponding to 2018 to 2021. Anonymized patients diagnosed with influenza virus (FLU), human parainfluenza virus (HPIV), human respiratory syncytial virus (HRSV), SARS-CoV-2 virus, or human adenovirus (HAdV) were included. We conducted chi-square goodness-of-fit tests for each virus by year, and a p-value of <0.05 was considered statistically significant.</div></div><div><h3>Results</h3><div>All analyzed respiratory viruses presented reduced case numbers during the COVID-19 pandemic, except FLU, which showed an increase of four cases in 2021 compared to 2019. For most viruses, the lowest incidence of confirmed cases was found in 2020. Furthermore, when excluding SARS-CoV-2, HRSV presented the most positive cases during the studied period, except in 2020. Besides SARS-CoV-2, the FLU was the only other respiratory virus that recorded deaths. It was also possible to observe that the number of SARS-CoV-2 cases reduced from April 2021.</div></div><div><h3>Conclusions</h3><div>We observed that most respiratory tract viral infections decreased during the COVID-19 pandemic, and this result may be associated with the public interventions for containing the COVID-19 pandemic. Moreover, the reduction of these other viruses may have resulted from the measures for prevention conducted by HCPA.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 4","pages":"Article 100190"},"PeriodicalIF":1.6,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142319102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Performance evaluation of four kits for the detection of neutralizing antibody against SARS-CoV-2 in human serum 检测人血清中 SARS-CoV-2 中和抗体的四种试剂盒的性能评估

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2024-09-13 DOI: 10.1016/j.jcvp.2024.100192

Hui Zhen , Ya Cheng , Qimeng Sun, Ying Zheng, Lili Tian, Chao Shen, Li Li, Jie Gong, Yonggang Chen, Hongping Ba

To evaluate four novel SARS-CoV-2 neutralizing antibody assay kits' application in neutralizing antibodies of population. Questionnaires from the voluntary participating researchers and selected the qualified questionnaires to analyse. For negative and positive coincidence rate, four novel SARS-Cov-2 neutralization antibody assay kits were tested. For within-run and between-run Precision verification study, four serum samples with two high and two low titer neutralizing antibodies were used to analyse. Based on the questionnaires, 175 qualified samples were divided into two groups. (1) negative neutralizing antibodies group: 31 samples had not been infected with the novel SARS-Cov-2 nor received the vaccine within the past one year; (2) positive neutralizing antibodies group: 144 samples were infected by COVID-19. There was 28 negative and 3 positive neutralizing antibodies of the individuals among the 31 negative samples which based on the questionnaires. The negative rates of 28 negative individules tested by GenScript, Vazyme and Hygeianey were 82.14 %, 60.71 % and 17.85 %, while the positive rates of the 147 positive samples were 93.87 %, 95.23 % and 100 %. The within-run coefficient of variations (C·V) of PBNAs, GenScript, Vazyme and Hygeianey were 11.49 %, 9.12 %, 7.97 % and 7.48 %, while the between-run coefficient of variations (C·V) were 21.37 %, 14.21 %, 12.29 % and 11.78 %. Due to the large within-run and between-run coefficient of variations, PBNAs was not suitable for large-scale promotion, while ELISAs could be leveraged for routine monitoring the titer of neutralizing antibodies against SARS-CoV-2.

评估四种新型 SARS-CoV-2 中和抗体检测试剂盒在人群中和抗体中的应用。向自愿参与的研究人员发放问卷，并选择合格的问卷进行分析。对四种新型 SARS-CoV-2 中和抗体检测试剂盒进行阴性和阳性重合率测试。在运行内和运行间的精密度验证研究中，使用了四份血清样本，分别含有两个高滴度和两个低滴度的中和抗体。根据调查问卷，175 份合格样本被分为两组。(1）中和抗体阴性组：31 个样本在过去一年内没有感染过新型 SARS-Cov-2，也没有接种过疫苗；（2）中和抗体阳性组：144 个样本感染了 COVID-19。在 31 个阴性样本中，有 28 人的中和抗体为阴性，3 人的中和抗体为阳性。由 GenScript、Vazyme 和 Hygeianey 检测的 28 个阴性个体的阴性率分别为 82.14 %、60.71 % 和 17.85 %，而 147 个阳性样本的阳性率分别为 93.87 %、95.23 % 和 100 %。PBNAs、GenScript、Vazyme 和 Hygeianey 的检出限内变异系数（C-V）分别为 11.49 %、9.12 %、7.97 % 和 7.48 %，而检出限间变异系数（C-V）分别为 21.37 %、14.21 %、12.29 % 和 11.78 %。由于运行内和运行间变异系数较大，PBNAs 不适合大规模推广，而 ELISAs 可用于常规监测 SARS-CoV-2 中和抗体滴度。

{"title":"Performance evaluation of four kits for the detection of neutralizing antibody against SARS-CoV-2 in human serum","authors":"Hui Zhen , Ya Cheng , Qimeng Sun, Ying Zheng, Lili Tian, Chao Shen, Li Li, Jie Gong, Yonggang Chen, Hongping Ba","doi":"10.1016/j.jcvp.2024.100192","DOIUrl":"10.1016/j.jcvp.2024.100192","url":null,"abstract":"<div><p>To evaluate four novel SARS-CoV-2 neutralizing antibody assay kits' application in neutralizing antibodies of population. Questionnaires from the voluntary participating researchers and selected the qualified questionnaires to analyse. For negative and positive coincidence rate, four novel SARS-Cov-2 neutralization antibody assay kits were tested. For within-run and between-run Precision verification study, four serum samples with two high and two low titer neutralizing antibodies were used to analyse. Based on the questionnaires, 175 qualified samples were divided into two groups. (1) negative neutralizing antibodies group: 31 samples had not been infected with the novel SARS-Cov-2 nor received the vaccine within the past one year; (2) positive neutralizing antibodies group: 144 samples were infected by COVID-19. There was 28 negative and 3 positive neutralizing antibodies of the individuals among the 31 negative samples which based on the questionnaires. The negative rates of 28 negative individules tested by GenScript, Vazyme and Hygeianey were 82.14 %, 60.71 % and 17.85 %, while the positive rates of the 147 positive samples were 93.87 %, 95.23 % and 100 %. The within-run coefficient of variations (C·V) of PBNAs, GenScript, Vazyme and Hygeianey were 11.49 %, 9.12 %, 7.97 % and 7.48 %, while the between-run coefficient of variations (C·V) were 21.37 %, 14.21 %, 12.29 % and 11.78 %. Due to the large within-run and between-run coefficient of variations, PBNAs was not suitable for large-scale promotion, while ELISAs could be leveraged for routine monitoring the titer of neutralizing antibodies against SARS-CoV-2.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 4","pages":"Article 100192"},"PeriodicalIF":1.6,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667038024000176/pdfft?md5=3e552214716ffe9cd0199a6acb5dc419&pid=1-s2.0-S2667038024000176-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142270719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular characterization of the genome of a new bunyavirus isolated in 2023 in Huzhou, China 2023 年在中国湖州分离到的一种新型布尼亚病毒基因组的分子鉴定

IF 1.6 Q4 INFECTIOUS DISEASES

Journal of clinical virology plus

Pub Date : 2024-08-01 DOI: 10.1016/j.jcvp.2024.100188

Shili Song , Zhang Shen , Deshun Xu

The novel bunyavirus (SFTSV) causes severe fever with thrombocytopenia syndrome (SFTS), which has a high mortality rate and poses a serious threat to public health. To investigate the genomic characteristics of SFTSV strains isolated in Huzhou, China, in 2023, we sequenced SFTSV isolates and constructed a phylogenetic tree, and analyzed their homologies, average genetic distances, and amino acid (aa) mutations using DNAstar and MEGA software. The two SFTSV strains belonged to genotypes A and D. The nucleotide (nt) and aa sequence similarities of the two strains were 96.61% and 98.64%, respectively. The nt and aa sequence homologies with human reference strains of the same genotypes were 94.44% and 97.28%, respectively. The nt and aa sequence homologies with syngeneic tick host reference strains were 94.56% and 97.96%, respectively. The two SFTSV isolates had different mutation rates in the L, M, and S proteins; the M protein exhibited the highest mutation rate. Further investigations of SFTSV are warranted to explore the distributions of its genotypes, as well as its nt and aa mutations.

新型布尼亚病毒（SFTSV）可导致严重发热伴血小板减少综合征（SFTS），该病死亡率高，严重威胁公众健康。为了研究2023年在中国湖州分离到的SFTSV毒株的基因组特征，我们对SFTSV分离株进行了测序，构建了系统发生树，并使用DNAstar和MEGA软件分析了它们的同源性、平均遗传距离和氨基酸（aa）突变。两株SFTSV分别属于基因型A和D，其核苷酸（nt）和aa序列相似度分别为96.61%和98.64%。与相同基因型的人类参考株的 nt 和 aa 序列同源性分别为 94.44% 和 97.28%。与合成蜱宿主参考菌株的 nt 和 aa 序列同源性分别为 94.56% 和 97.96%。两种 SFTSV 分离物的 L、M 和 S 蛋白的突变率不同，其中 M 蛋白的突变率最高。有必要对SFTSV进行进一步研究，以探索其基因型的分布及其nt和aa突变。

{"title":"Molecular characterization of the genome of a new bunyavirus isolated in 2023 in Huzhou, China","authors":"Shili Song , Zhang Shen , Deshun Xu","doi":"10.1016/j.jcvp.2024.100188","DOIUrl":"10.1016/j.jcvp.2024.100188","url":null,"abstract":"<div><p>The novel bunyavirus (SFTSV) causes severe fever with thrombocytopenia syndrome (SFTS), which has a high mortality rate and poses a serious threat to public health. To investigate the genomic characteristics of SFTSV strains isolated in Huzhou, China, in 2023, we sequenced SFTSV isolates and constructed a phylogenetic tree, and analyzed their homologies, average genetic distances, and amino acid (aa) mutations using DNAstar and MEGA software. The two SFTSV strains belonged to genotypes A and D. The nucleotide (nt) and aa sequence similarities of the two strains were 96.61% and 98.64%, respectively. The nt and aa sequence homologies with human reference strains of the same genotypes were 94.44% and 97.28%, respectively. The nt and aa sequence homologies with syngeneic tick host reference strains were 94.56% and 97.96%, respectively. The two SFTSV isolates had different mutation rates in the L, M, and S proteins; the M protein exhibited the highest mutation rate. Further investigations of SFTSV are warranted to explore the distributions of its genotypes, as well as its nt and aa mutations.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 3","pages":"Article 100188"},"PeriodicalIF":1.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667038024000139/pdfft?md5=49f55ea12b1e5562ede24ca60f1f110c&pid=1-s2.0-S2667038024000139-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141845067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0